NEW YORK (Reuters Health) – For patients with type 2 diabetes not controlled with metformin and a sulfonylurea, the choice of an additional agent should be based on…
NEW YORK (Reuters Health) – In patients with impaired renal function, the type of nonionic contrast agent used for coronary angiography seems to make little difference to the…
NEW YORK (Reuters Health) – Cotreatment with an angiotensin-converting enzyme (ACE) inhibitor reduces the risk of diabetes associated with beta blocker treatment, according to a report in the…
NEW YORK (Reuters Health) – In a phase 2 study of patients with diabetic macular edema (DME), intravitreal injections of the vascular endothelial growth factor inhibitor, VEGF Trap-Eye,…
NEW YORK (Reuters Health) – Percutaneous coronary intervention with bare metal stents followed by a course of oral prednisone at immunosuppressive strength produces results comparable to that obtained…
NEW YORK (Reuters health) – Among premenopausal women treated for hormone-responsive breast cancer with adjuvant anastrozole, body mass index (BMI) has a significant impact on outcomes, an Austrian…
NEW YORK (Reuters Health) – Compared with the standard long protocol using gonadotrophin-releasing hormone (GnRH) agonists during ovarian stimulation, the use of GnRH antagonists results in comparable live-birth…
NEW YORK (Reuters Health) – In ischemic stroke patients weighing more than 100 kg, the fixed maximum dose limit for intravenous recombinant tissue plasminogen activator (rTPA — alteplase)…
NEW YORK (Reuters Health) – There’s now one more reason for statin loading before percutaneous coronary intervention. As well as reducing myocardial damage, high-dose atorvastatin given shortly before…
NEW YORK (Reuters Health) – Clonidine in the form of extended-release tablets improves response to psychostimulant treatment in children and adolescents with attention-deficit/hyperactivity disorder, results of a phase…
